Search Results - technology+classifications+%3e+human+health+care+%3e+therapeutics

121 Results Sort By:
rAAV Gene Therapy for Myotonic Dystrophy
Utilizes rAAV Expression of Human Muscleblind ProteinsThis gene therapy employs recombinant adeno-associated viruses (rAAVs) that express human muscleblind proteins, treating myotonic dystrophy and other diseases caused by repeat microsatellite mutation expressions in coding and non-coding regions. Myotonic dystrophy is a dominantly inherited multi-systemic...
Published: 6/22/2026   |   Updated: 6/22/2026   |   Inventor(s): Charles Thornton, Rahul Kanadia, Maurice Swanson
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
Anti-Viral Agent for Treating Relapsed or Refractory AML and MDS through Immune System Activation
Harnesses the Body’s Own Immune Response Against Malignant Cells to Cause Disease Regression See how the abacavir binds to HLA-B*57:01 here. This antiviral agent stimulates patients’ own immune system against malignant cells to cause disease regression. Cancer remains one of the most costly and challenging diseases to treat, particularly...
Published: 6/22/2026   |   Updated: 6/22/2026   |   Inventor(s): David Ostrov, Christopher Cogle
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
Antigen-Specific Immune Tolerance Immunotherapy for Multiple Sclerosis
Codon-Optimized Myelin Autoantigen Sequences Including MOG, PLP, and MBP This first-in-class antigen-specific immunotherapy is designed to restore immune homeostasis in multiple sclerosis (MS) patients through the in vivo induction of myelin-specific regulatory T cells (Tregs). By selectively reprogramming pathogenic immune responses while preserving...
Published: 6/15/2026   |   Updated: 5/28/2026   |   Inventor(s): Brad Hoffman
Keywords(s):  
Category(s): Technology Classifications, Technology Classifications > Human Health Care > Therapeutics
Targeted Anti-ROR2 Antibodies for Precision Cancer Therapy
Enables Selective Targeting of ROR2-Positive Tumors Using High-Affinity Antibodies and Antibody-Drug Conjugates These targeted anti-ROR2 antibodies enable precision cancer therapy by selectively engaging ROR2-positive tumors with high-affinity antibodies and antibody-drug conjugates (ADCs). The ADC market is projected to grow from $13.5 billion to...
Published: 6/15/2026   |   Updated: 5/18/2026   |   Inventor(s): Christoph Rader, Xiuling Li, Haiyong Peng
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Diagnostics, Technology Classifications > Human Health Care > Therapeutics
Siglec-6 Targeting Antibodies for Precision Immunotherapy
Antibody-Based Platform for Targeted Elimination of Leukemia Cells with Reduced Off-Target Toxicity These human antibodies target and bind to Siglec-6 for precise immunotherapies treating diseases related to aberrant Siglec-6 expression, such as chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia (CLL) is one of the most common adult leukemias,...
Published: 6/12/2026   |   Updated: 5/14/2026   |   Inventor(s): Christoph Rader, Matthew Cyr
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Diagnostics, Technology Classifications > Human Health Care > Therapeutics
Metabolically Stable Sigma Receptor and Opioid Receptor Modulators for Treating Addiction
Dual-Action Small Molecules Target Withdrawal and Craving to Combat Opioid Use Disorder These sigma receptors and opioid receptor modulators present improved metabolic stability and bioavailability for treating opioid addiction. While opioid preparations such as morphine have been mainstays for pain management since the early 1800s, overprescribing...
Published: 3/26/2026   |   Updated: 3/26/2026   |   Inventor(s): Christopher McCurdy, Hebaalla Agha, Sebastiano Intagliata, Morgan Crowley, Sushobhan Mukhopadhyay, Sampa Gupta, Sarah Burns
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
Polymerase-Theta Inhibition for Treating Epstein-Barr Virus (EBV) Cancers and Related Diseases
Proteolysis Targeting Chimeras (PROTACs) Block Microhomology or Theta-Mediated End Joining in Cancer Cells These polymerase theta inhibitors treat Epstein-Barr virus (EBV)-associated cancers and related diseases. EBV cancers are linked to two percent of the global cancer burden and are difficult to treat, demonstrating a strong need for effective...
Published: 4/13/2026   |   Updated: 3/18/2026   |   Inventor(s): Sumita Bhaduri-McIntosh, Michael McIntosh, Guangrong Zheng, Hui Chen
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
Anodization Tool for Uniform Titanium Oxide Nanotubes on Non-Conductive Surfaces, Enabling Advanced Dental Implants and Biomedical Devices
Produces Titanium Oxide Nanotubes, Enhancing Dental Implants with Antibacterial and Biocompatible Properties Dental implants and other load-bearing biomedical devices rely heavily on surface properties to achieve long-term stability, osseointegration, and resistance to bacterial colonization. These are important aspects of modern dentistry that impact...
Published: 4/13/2026   |   Updated: 3/16/2026   |   Inventor(s): Josephine Esquivel-Upshaw, Fan Ren, Chao-Ching Chiang
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
Combination Genetic Engineered Cell Therapy for Targeted Immune Protection of Stem Cell-Derived Beta Cells
Localized Immune Tolerance for Safer and Effective Type 1 Diabetes Therapy This engineered cell therapy combination was developed to treat Type 1 diabetes. Type 1 diabetes (T1D) is a chronic autoimmune disease caused by an autoimmune attack on the insulin-producing pancreatic beta cells. It affects approximately 8.4 million people worldwide, with prevalence...
Published: 3/10/2026   |   Updated: 3/6/2026   |   Inventor(s): Holger Russ, Leonardo Ferreira
Keywords(s):  
Category(s): Technology Classifications, Technology Classifications > Human Health Care > Therapeutics
Small-Molecule IL-6 Inhibitors Targeting gp130 for Anti-Cancer Therapy
Blocks IL-6-gp130 Signaling for Cost-Effective Treatment of Autoimmune Diseases and IL-6–Driven Cancers These small-molecule interleukin-6 (IL-6) inhibitors target glycoprotein 130 (gp130) by blocking IL-6-gp130 signaling, delivering a cost-effective therapy for autoimmune diseases and IL-6-driven cancers. IL-6-gp130 signaling drives tumor growth...
Published: 3/31/2026   |   Updated: 3/2/2026   |   Inventor(s): Chenglong Li, Liguang Mao, Daniel Schultz, Zhihang Shen, Xiaozhi Yang, Wei Zhou
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...